Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Day (February 2026)
16 slides from Arovella Therapeutics's investor day presentation, February 2026
Slide 1: Emergence 2026 Life Science Investor Day
ASX:ALA Emergence 2026 Life Science Investor Day
Slide 2: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. 4. Whilst this presentation is based on information from sources which are considered The presentation is not intended to be comprehensive or provide all information reliable, no representation or warr
Slide 3: ALA-101 (CAR19-iNKT): IND accepted by FDA
IND accepted by U.S. Food and Drug Administration (FDA) ALA is progressing towards its phase 1 study for ALA-101 Provides regulatory validation of ALA-101’s preclinical package, manufacturing process, Key operational and clinical development plan and regulatory ALA-101 (CAR19-iNKT) milestone Enables
Slide 4: Arovella's path to patient
Arovella’s path to patient TECHNOLOGY PRE-CLINICAL LENTIVIRUS MANUFACTURING PHASE 1 CLINICAL PHASE 2 CLINICAL PRODUCT FDA IND ACQUISITION CONFIRMATION MANUFACTURING PLATFORM TRIAL1 TRIAL CD19 CAR-iNKT Lymphoma FY 2026 ALA-101 CLDN18.2 CAR-iNKT Gastric cancer and pancreatic cancer ALA-105 CAR-iNKT Ot
Slide 5: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Feb-25 Acquisition In vivo CAR Preclinical undisclosed undisclosed $2,400 Oct-25 Acquisition In vivo CAR Preclinical2 $1,500 $0 $1,500 Aug-25
Slide 6: Cell therapy has revolutionised blood cancer treatment
Cell Therapy has revolutionised blood cancer treatment CAR-T cells have demonstrated their curative potential in blood cancers Cure Product Approval Year 2024 Revenue CAR-T cells have demonstrated ability to 2017 US$1570m3 cure haematological cancers 2017 US$442m4 Strong 2021 US$242m5 Sales 1. https
Slide 7: ALA's solution: 1 week
Current CAR-T technology challenges ALA’s solution: One CAR-T product only treats the patient who supplied the T cells One CAR-iNKT batch from Manufacturing & supply a healthy donor treats multiple T cell chain costs are high patients T cell Each manufacturing T cells can be compromised batch is due
Slide 8: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system Innate Immunity Adaptive Immunity ASX:ALA 8
Slide 9: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Properties make them ideal for use in cell therapy Strong safety profile Invariant receptor recognizes the same molecule (CD1d) in all people Innate Don’t cause graft versus host disease (GvHD)1 Immunity Robust killers Bridge the rapid innate
Slide 10: A differentiated position
A differentiated position T cell and NK cell sectors are competitive T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. ASX:ALA Source: Company analysis based on public information 10
Slide 11: Arovella's expanding pipeline
Arovella’s expanding pipeline ALA-101 ALA-105 Upcoming Commence phase 1 clinical trial Generate preclinical data for the Milestones for patients with CD19-positive CLDN18.2 CAR in iNKT cells with lymphoma and leukaemia the addition of IL-12-TM armour ASX:ALA 11
Slide 12: Investment highlights
Investment highlights ALA-101 (CAR19-iNKT) ALA-105 (CLDN18.2 CAR-iNKT) • Clinic ready, following U.S. FDA • Promising data generated for acceptance of the IND, validating Arovella’s CAR targeting CLDN18.2 preclinical and manufacturing data • The CAR will be incorporated into iNKT • Phase 1 clinical
Slide 13: Strong Leadership Team
Strong Leadership Team SENIOR MANAGEMENT TEAM Dr Michael Baker Dr Nicole van der Weerden Dr Robson Dossa Dr Michelle Ferguson Jacqueline Cumming CEO & MANAGING DIRECTOR CHIEF OPERATING OFFICER VP MANUFACTURING & QUALITY SENIOR DIRECTOR RESEARCH & SENIOR DIRECTOR CLINICAL DEVELOPMENT DEVELOPMENT BOAR
Slide 14: Financial overview
Financial overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA Market capitalisation1 $112.08 million 40,000,000 Shares on issue 1,205.1 million $0.18 52-week low / high $0.068 / $0.1950 30,000,000 Cash Balance (31 Dec, 2025) $19.4 million $0.12 Major Shareholders 20,000,000 Sh
Slide 15: Thank You
ASX:ALA Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 16: Cell therapy deal references
Cell therapy deal references 1. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies 2. https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbit